Response to "Evaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicity"

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 158-

  Carleton, B C ^a,b,c   Ross, C J ^a,b,c   Bhavsar, A P ^b,c   Lee, J W ^a,b,c   Visscher, H ^d   Rassekh, S R ^a,c   Hayden, M R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

COMT GENE; GENE; GENE INTERACTION; GENETIC RISK; HEARING IMPAIRMENT; HETEROZYGOTE; HUMAN; LETTER; METABOLOMICS; OTOTOXICITY; PHARMACOGENETICS; PRIORITY JOURNAL; TPMT GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; METHYLTRANSFERASES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84904855333     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.90     Document Type: Letter

References (6)

1. Lanvers-Kaminsky, C., Malath, I., Deuster, D., Ciarimboli, G., Boos, J. & am Zehnhoff-Dinnesen, A.G. Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity. Clin. Pharmacol. Ther. e-pub ahead of print, 16 April, 2014
2. Pussegoda, K. et al.; CPNDS Consortium Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94, 243-251 (2013
3. Yang, J.J. et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-259 (2013
4. Carleton, B.C. et al. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin. Pharmacol. Ther. 95, 253 (2014
5. von Stechow, L. et al. Identification of cisplatinregulated metabolic pathways in pluripotent stem cells. PLoS One 8, e76476 (2013
6. Kolinsky, D.C., Hayashi, S.S., Karzon, R., Mao, J. & Hayashi, R.J. Late onset hearing loss: A significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J. Pediatr. Hematol. Oncol. 32, 119-123 (2010.